BsAb-based Pretargeting System

Creative biolabs possesses the most advanced techniques and experienced scientists in recombinant antibody engineering, which enable us to provide custom services for bispecific antibodies (BsAbs) application in pretargeted radioimmaging and radioimmunotherapy.

Figure: BsAb-based pretargeting system (Leukemia, 2005)

Radioconjugates have been used in imaging and treating cancers for many years, however, many radionuclides coupled large molecules trapped in kidneys are hard to be excreted. In order to solve this problem, BsAb-based pretargeting can be used as an alternative strategy. In this strategy, antibody is first administered to target tumor cells, after which the radioactivity is given. In general, the BsAb has one binding domain targeting an antigen and the other one targeting a hapten, such as HSG. The radioactivity is a conjugate composed of hapten peptides and radionuclides, and sometimes single DOTA moiety is used to stable radionuclides (shown in the figure). Compared to conventional direct targeting modality, BsAb-based pretargeting can improve therapeutic responses and achieve rapid renal excretion.

As a global provider in antibody field, Creative Biolabs can provide you with desired BsAbs for scientific and clinical purposes according to every client`s individual requirements.

Reference

1. RM Sharkey, et al. Improved therapy of non-Hodgkin''s lymphoma xenografts using radionuclides pretargeted with a new anti-CD20bispecific antibody. Leukemia. 2005 Jun;19(6):1064-9.

For research use only. Not intended for any clinical use.